Effect of Magnesium Supplementation on Circulating Biomarkers of Cardiovascular Disease

被引:8
|
作者
Alonso, Alvaro [1 ]
Chen, Lin Y. [2 ]
Rudser, Kyle D. [3 ]
Norby, Faye L. [4 ]
Rooney, Mary R. [5 ]
Lutsey, Pamela L. [4 ]
机构
[1] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA
[2] Univ Minnesota, Dept Med, Cardiovasc Div, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA
[4] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA
[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21287 USA
基金
美国国家卫生研究院;
关键词
magnesium; proteomics; randomized trial; DIETARY MAGNESIUM; METAANALYSIS; FAMILY; SERUM; RISK; ST2;
D O I
10.3390/nu12061697
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
(1) Background: Magnesium supplementation may be effective for the prevention of cardiometabolic diseases, but the mechanisms are unclear. Proteomic approaches can assist in identifying the underlying mechanisms. (2) Methods: We collected repeated blood samples from 52 individuals enrolled in a double-blind trial which randomized participants 1:1 to oral magnesium supplementation (400 mg magnesium/day in the form of magnesium oxide) or a matching placebo for 10 weeks. Plasma levels of 91 proteins were measured at baseline with follow-up samples using the Olink Cardiovascular Disease III proximity extension assay panel and were modeled as arbitrary units in a log(2)scale. We evaluated the effect of oral magnesium supplementation for changes in protein levels and the baseline association between serum magnesium and protein levels. The Holm procedure was used to adjust for multiple comparisons. (3) Results: Participants were 73% women, 94% white, and had a mean age of 62. Changes in proteins did not significantly differ between the two intervention groups after correction for multiple comparisons. The most statistically significant effects were on myoglobin [difference -0.319 log(2)units, 95% confidence interval (CI) (-0.550, -0.088),p =0.008], tartrate-resistant acid phosphatase type 5 (-0.187, (-0.328, -0.045),p =0.011), tumor necrosis factor ligand superfamily member 13B (-0.181, (-0.332, -0.031),p =0.019), ST2 protein (-0.198, (-0.363, -0.032),p =0.020), and interleukin-1 receptor type 1 (-0.144, (-0.273, -0.015),p =0.029). Similarly, none of the associations of baseline serum magnesium with protein levels were significant after correction for multiple comparisons. (4) Conclusions: Although we did not identify statistically significant effects of oral magnesium supplementation in this relatively small study, this study demonstrates the value of proteomic approaches for the investigation of mechanisms underlying the beneficial effects of magnesium supplementation. Clinical Trials Registration: ClinicalTrials.gov NCT02837328.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Circulating biomarkers in cardiovascular disease
    Ingelsson, Erik
    DISEASE MARKERS, 2009, 26 (5-6) : 197 - 198
  • [2] Circulating Biomarkers for Cardiovascular Disease Risk Prediction in Patients With Cardiovascular Disease
    Wong, Yuen-Kwun
    Tse, Hung-Fat
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [3] RIBOFLAVIN SUPPLEMENTATION AND BIOMARKERS OF CARDIOVASCULAR DISEASE IN THE ELDERLY
    Tavares, Nelson R.
    ANNALS OF NUTRITION AND METABOLISM, 2009, 55 : 84 - 84
  • [4] Riboflavin supplementation and biomarkers of cardiovascular disease in the elderly
    N. R. Tavares
    P. A. Moreira
    T. F. Amaral
    JNHA - The Journal of Nutrition, Health and Aging, 2009, 13 : 441 - 446
  • [5] Riboflavin supplementation and biomarkers of cardiovascular disease in the elderly
    Tavares, N. R.
    Moreira, P. A.
    Amaral, T. F.
    JOURNAL OF NUTRITION HEALTH & AGING, 2009, 13 (05): : 441 - 446
  • [6] Epigenetic Biomarkers and Cardiovascular Disease: Circulating MicroRNAs
    de Gonzalo-Calvo, David
    Iglesias-Gutierrez, Eduardo
    Llorente-Cortes, Vicenta
    REVISTA ESPANOLA DE CARDIOLOGIA, 2017, 70 (09): : 763 - 769
  • [7] Candidate circulating biomarkers for the cardiovascular disease continuum
    Dotsenko, Olena
    Chackathayil, Julia
    Patel, Jeetesh V.
    Gill, Paramjit S.
    Lip, Gregory Y. H.
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (24) : 2445 - 2461
  • [8] Circulating Exosomes as Potential Biomarkers in Cardiovascular Disease
    Parizadeh, Seyed Mostafa
    Jafarzadeh-Esfehani, Reza
    Ghandehari, Maryam
    Parizadeh, Seyed Mohammad Reza
    Hassanian, Seyed Mahdi
    Rezayi, Majid
    Ghayour-Mobarhan, Majid
    Ferns, Gordon A.
    Avan, Amir
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (37) : 4436 - 4444
  • [9] Sex Differences in Circulating Biomarkers of Cardiovascular Disease
    Lau, Emily S.
    Paniagua, Samantha M.
    Guseh, James Sawalla
    Bhambhani, Vijeta
    Zanni, Markella V.
    Courchesne, Paul
    Lyass, Asya
    Larson, Martin G.
    Levy, Daniel
    Ho, Jennifer E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (12) : 1543 - 1553
  • [10] Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury
    Viereck, Janika
    Thum, Thomas
    CIRCULATION RESEARCH, 2017, 120 (02) : 381 - 399